Fisher Douglas Carl 4

4 · CERO THERAPEUTICS HOLDINGS, INC. · Filed Feb 16, 2024

Insider Transaction Report

Form 4
Period: 2024-02-14
Transactions
  • Other

    Warrants

    2024-02-14+5,0005,000 total
    Exercise: $11.50From: 2024-03-15Exp: 2029-02-14Common Stock (5,000 underlying)
  • Other

    Class A Common Stock

    2024-02-14+43,30043,300 total
  • Award

    Series A Convertible Preferred Stock

    2024-02-14$1000.00/sh+50$50,00050 total
    Exercise: $10.00Common Stock (5,000 underlying)
Footnotes (2)
  • [F1]Represents shares of Class A Common Stock or warrants, as applicable, distributed in-kind by Phoenix Biotech Sponsor, LLC (the "Sponsor") to its members, pro rata and without consideration.
  • [F2]On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date.

Documents

1 file
  • 4
    ownership.xmlPrimary